Impact ledger
Pfizer Inc. (PFE)
31 events mapped to this ticker since 2026-06-12.
Event impact log
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-07-16 | Event | While J&J's specific drug successes are not directly competitive with Pfizer's primary growth drivers, the overall positive sentiment for large-cap pharma due to strong drug performance could provide a minor halo effect or indicate robust healthcare spending. | watch | 1-3m | 0.20 |
| 2026-07-15 | Event | Increased competitive pressure in the oncology market from a strengthened GSK pipeline, potentially impacting future market share. | watch | 1-3m | 0.30 |
| 2026-07-15 | Event | Increased competitive pressure in the oncology market, particularly in precision oncology, from a strengthened GSK. | watch | 1-5y | 0.20 |
| 2026-07-15 | Event | Similar to Merck, Pfizer could face increased competition or be prompted to evaluate its own M&A strategy in response to GSK's move. | watch | 1-5y | 0.30 |
| 2026-07-15 | Event | Increased competitive pressure in the oncology market from JNJ's enhanced pipeline. | watch | 1-5y | 0.30 |
| 2026-07-15 | Event | Peer performance comparison, particularly in pharmaceutical and medical device segments. JNJ's results may indicate sector trends. | watch | 1-5d | 0.40 |
| 2026-07-15 | Event | Increased competition in the oncology market, particularly in NSCLC, from a strengthened GSK pipeline. | watch | 1-5y | 0.20 |
| 2026-07-15 | Event | Potential competitive pressure in the oncology market, specifically within breast cancer treatments, though REVTORPYK targets a specific wild-type population. | watch | 1-3m | 0.20 |
| 2026-07-14 | Event | Similar to Moderna, Pfizer has a significant presence in oncology. Valion Bio's entry into oncology supportive care, even if nascent, represents a potential new competitor in a segment of the oncology market. The focus on biodefense also highlights a growing area of government spending that large ph | watch | 1-5y | 0.20 |
| 2026-07-13 | Event | Increased competition in the global vaccine market, particularly for emerging infectious diseases, potentially impacting future market share or pricing power for similar products. | watch | 1-5y | 0.30 |
| 2026-07-13 | Event | Increased competitive pressure in the broader pharmaceutical market, particularly for companies with pipeline assets in metabolic diseases or those reliant on older blockbuster drugs. | watch | 1-5y | 0.40 |
| 2026-07-11 | Event | Indirect competitive pressure and investor re-evaluation of oral GLP-1 market potential. Pfizer has its own oral GLP-1 candidates in development. NVO's struggles with oral Wegovy could signal challenges or opportunities for Pfizer's own program. | watch | 3-12m | 0.30 |
| 2026-07-07 | Event | Increased institutional demand for high-dividend healthcare stocks, benefiting from the rotation into defensive, income-generating assets. | Bullish | 1-3m | 0.55 |
| 2026-07-06 | Event | Similar to Merck, increased competitive pressure in the oncology market. May prompt Pfizer to evaluate its own pipeline and M&A strategy. | watch | 1-5y | 0.30 |
| 2026-07-06 | Event | Pfizer, a major player in oncology, might face increased competitive pressure in the long term if Novartis successfully develops Myricx Bio's NMTi assets. In the short term, it reinforces the strategic importance of pipeline diversification and M&A in the oncology space, potentially influencing Pfiz | watch | 1-3m | 0.30 |
| 2026-07-06 | Event | Increased competitive pressure in the oncology market, particularly in novel mechanisms of action. May prompt similar strategic moves. | watch | 1-3m | 0.30 |
| 2026-06-30 | Event | Aggressive M&A strategy to counter significant upcoming patent expirations, potentially leading to higher debt, integration challenges, but also new revenue streams. | mixed | 1-5y | 0.70 |
| 2026-06-30 | Event | Reduced sales potential for Abrilada (Pfizer's Humira biosimilar) if patient re-switching to branded Humira is a prevalent trend, impacting revenue forecasts for their biosimilar portfolio. | Bearish | 1-3m | 0.40 |
| 2026-06-26 | Event | Similar to Merck, J&J's strategic shift and investment in biologics could heighten competition and potentially impact pricing power or market share in certain segments where Pfizer also operates. | watch | 1-3m | 0.40 |
| 2026-06-26 | Event | Similar to Merck, Pfizer's substantial presence in the Chinese pharmaceutical market could expose it to heightened tax audit risks and potential financial adjustments. | watch | 3-12m | 0.30 |
| 2026-06-25 | Event | Potential for future entry or partnership in the HPV vaccine market, or impact on other vaccine segments due to increased focus on preventative health. | watch | 3-12m | 0.40 |
| 2026-06-24 | Event | Competitive landscape shift in oncology | watch | 3-12m | 0.30 |
| 2026-06-24 | Event | Avoidance of significant legal liabilities, including potential damages and ongoing royalty payments, related to Paxlovid sales. | Bullish | 1-5y | 0.60 |
| 2026-06-23 | Event | Pfizer, like other large pharmaceutical firms, might consider belapectin as a pipeline enhancement, particularly given its late-stage development and the significant market opportunity in MASH. | watch | 3-12m | 0.20 |
| 2026-06-22 | Event | Potential acquirer or partner for rare disease assets, though JAGX's crofelemer is a small asset for a company of this size. | watch | 3-12m | 0.10 |
| 2026-06-22 | Event | Potential competitive pressure in the antidepressant market, particularly for novel mechanisms or improved efficacy/tolerability profiles. Pfizer has a presence in neuroscience. | watch | 3-12m | 0.20 |
| 2026-06-17 | Event | Increased competition in the flu vaccine market, potential for market share shifts. | watch | 3-12m | 0.40 |
| 2026-06-17 | Event | While not a current market leader, Pfizer is developing oral GLP-1 candidates. Increased market size and adoption, particularly for oral forms, could provide a significant opportunity if their pipeline candidates succeed. | watch | 3-12m | 0.60 |
| 2026-06-17 | Event | Potential for competitive pressure on existing and pipeline obesity/metabolic drugs. Success or failure of their oral GLP-1 candidate (danuglipron) will significantly impact future revenue streams. Increased R&D spending to compete. | watch | 1-5y | 0.50 |
| 2026-06-12 | Event | Similar to Merck, increased M&A competition could affect Pfizer's ability to acquire promising assets at favorable valuations, or spur them to accelerate their own M&A strategy. | watch | 1-3m | 0.30 |
| 2026-06-12 | Event | Competitive pressure and industry trend. BMY's aggressive cost-cutting may signal a broader industry imperative for efficiency in the face of patent cliffs, potentially pressuring peers to follow suit. | watch | 3-12m | 0.30 |
This ledger is regenerated from Market Ontology's public event pipeline. For live alerts on new assumption changes for PFE, start a trial or view the PFE entity page.